Newron Pharmaceuticals announced last week the successful completion of patient enrollment in its Phase 2/3 trial of Sarizotan for the Treatment of Apneas in Rett Syndrome. The Company expects to report top line results from the trial in Q4 2019.
A very low rate of discontinuation due to adverse events or lack of efficacy was reported and approximately 90% of patients who completed the 6 month double-blind period continued in the long-term open-label extension study.
The 129 patient trial commenced in August 2016 and was held over 15 centres in United States, UK, Italy, India and Australia.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)